AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,640.50GBp
12:03pm EDT
Change (% chg)

14.00p (+0.30%)
Prev Close
4,626.50p
Open
4,613.50p
Day's High
4,677.50p
Day's Low
4,602.00p
Volume
2,415,551
Avg. Vol
2,670,878
52-wk High
4,946.41p
52-wk Low
3,718.50p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes... (more)

Overall

Beta: 0.38
Market Cap(Mil.): £58,414.88
Shares Outstanding(Mil.): 1,263.29
Dividend: 125.00
Yield (%): 3.85

Financials

  AZN.L Industry Sector
P/E (TTM): 70.21 40.70 41.18
EPS (TTM): 0.66 -- --
ROI: 3.05 16.89 16.23
ROE: 5.75 17.42 17.07
Search Stocks

BRIEF-AstraZeneca to collaborate with Harvard Stem Cell Institute in diabetes

* To collaborate with Harvard Stem Cell Institute in diabetesFurther company coverage: (Reporting By Ben Hirschler)

25 Mar 2015

BRIEF-AstraZeneca announces collaboration with Japan's Daiichi Sankyo

* Under terms of agreement, Daiichi Sankyo Inc will pay a $200 mln up-front fee and subsequent sales-related payments of up to $625 mln

19 Mar 2015

AstraZeneca two-in-one drug succeeds in lung disease test

LONDON - AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials, boosting hopes for the company's respiratory pipeline.

18 Mar 2015

AstraZeneca two-in-one drug succeeds in lung disease test

LONDON, March 18 - AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials, boosting hopes for the company's respiratory pipeline.

18 Mar 2015

BRIEF-AstraZeneca reports positive Phase III results for PT003 in COPD

* PT003 is first LAMA/LABA combination to be delivered in a pressurised metered dose inhaler

18 Mar 2015

AstraZeneca heart drug results positive but not knock-out

LONDON - New clinical trial results with AstraZeneca's heart drug Brilinta are positive but bleeding risks suggest the company's sales force still has its work cut out to get the medicine widely adopted for long-term use.

16 Mar 2015

Long-term use of AstraZeneca heart drug brings benefits, some risks

LONDON - Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday.

14 Mar 2015

Long-term use of AstraZeneca heart drug brings benefits, some risks

LONDON, March 14 - Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday.

14 Mar 2015

TSB leads rise in UK stocks as Sabadell makes takeover bid

LONDON, March 12 - UK shares rose on Thursday, led by domestic bank TSB after it received a takeover offer, and by drugs group AstraZeneca on optimism about key trial results.

12 Mar 2015

TSB leads rise in UK stocks as Sabadell makes takeover bid

LONDON, March 12 - UK shares rose on Thursday, led by domestic bank TSB after it received a takeover offer, and by drugs group AstraZeneca on optimism about key trial results.

12 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks